Business description: Incyte Corporation

Incyte Corporation specializes in the research & development of therapeutic products mainly intended for the treatment of cancers and inflammatory disorders. Net sales break down by revenue source as follows:

- product sales (84.7%);

- royalties (12.4%);

- income from research and cooperation agreements (2.9%).

Number of employees: 2,844

Sales by Activity: Incyte Corporation

Fiscal Period: December 2021 (USD) 2022 (USD) 2023 (USD) 2024 (USD) 2025 (USD)

Oncology and Dermatology Pharmaceutical Products

2.99B 3.39B 3.7B 4.24B 5.14B

Geographical breakdown of sales: Incyte Corporation

Fiscal Period: December 2021 (USD) 2022 (USD) 2023 (USD) 2024 (USD) 2025 (USD)

United States

2.9B 3.2B 3.5B 4B 4.8B

Europe

124M 147M - 260M 324M

Other Countries

- - - 6.2M 17.57M

Europe and Japan

- - 179M - -

Executive Committee: Incyte Corporation

Manager TitleAgeSince
Chief Executive Officer 58 25/06/2025
Director of Finance/CFO 57 03/05/2026
President 62 04/06/2023
Chief Tech/Sci/R&D Officer 62 31/12/2015
Chief Tech/Sci/R&D Officer 59 01/03/2015

Composition of the Board of Directors: Incyte Corporation

Director TitleAgeSince
Chairman 59 25/06/2025
Director/Board Member 72 19/01/2015
Director/Board Member 64 19/01/2015
Director/Board Member 64 13/11/2017
Director/Board Member 73 15/12/2019
Director/Board Member 74 24/03/2020
Director/Board Member 66 26/09/2021
Director/Board Member 58 25/06/2025

Shareholders: Incyte Corporation

NameStocks%Valuation
Baker Bros. Advisors LP
15.54 %
31,040,841 15.54 % 3 519 M $
Baker Bros. Advisors LP
15.39 %
30,744,412 15.39 % 3 485 M $
BlackRock Advisors LLC
7.293 %
14,570,131 7.293 % 1 652 M $
Dodge & Cox
6.133 %
12,252,356 6.133 % 1 389 M $
Vanguard Capital Management LLC
5.471 %
10,930,066 5.471 % 1 239 M $

Holdings: Incyte Corporation

NameStocks%Valuation
4,372,1246.73% 23 M $

Company details: Incyte Corporation

Incyte Corp.

1801 Augustine Cut-Off

19803, Wilmington

+302 498 6700

http://www.incyte.com
address Incyte Corporation(INCY)

Biopharmaceuticals

Change 5-day change 1-year change 3-year change Capi.($)
-1.52%+1.37%+71.85%+80.89% 23.42B
+0.16%+2.39%+24.45%-6.10% 68.85B
-0.54%+1.02%+37.33%+189.96% 52.13B
-3.65%+34.50%+34.50%+34.50% 43.46B
-0.58%-0.23%-52.36%-53.82% 41.24B
-1.69%-2.81%+65.60%-26.04% 30.41B
-0.65%-8.37%+98.26%-50.79% 24.53B
+3.99%+3.12%+3.87%+200.81% 19.75B
+0.26%+0.39%+72.12%+126.52% 16.57B
-0.20%-1.93%+77.52%+136.24% 15.95B
Average -0.42%-1.45%+43.31%+63.22% 33.63B
Weighted average by Cap. -0.64%-0.69%+34.39%+50.12%
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
AA
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
26
Last Close Price
117.25USD
Average target price
113.82USD
Spread / Average Target
-2.93%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. INCY Stock
  4. Company Incyte Corporation